Avacta is a healthcare group developing innovative cancer drugs and powerful in vitro diagnostics to improve human health and well-being. Avacta’s Therapeutics division, based in White City, London, U.K. develops novel cancer therapies using its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families. Using the Affimer® platform Avacta is focusing on immunotherapies in the fight against cancer. Avacta’s Diagnostics division, based in Wetherby, UK., is using the Affimer® platform with the aim of developing market leading diagnostic products.